Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

2.700 -0.040 (-1.46%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio 
Via Benzinga
Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma
Dr. Gary S. Jacob, CEO of OKYO Pharma (NASDAQ: OKYO), was recently a guest on Benzinga’s All Access. 
Via Benzinga
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
Webull’s community of active participants can now access OKYO's profile on the leading mobile-first brokerage platform 
From OKYO Pharma LTD
Via GlobeNewswire
Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Unique Fabricating, Inc. (NYSE: UFAB) climbed 205% to $0.55 after gaining around 4% on Tuesday. 
Via Benzinga
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
Via ACCESSWIRE
Why ClearOne Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) gained 74.2% to $0.2701 in pre-market trading after gaining around 7% on Monday. 
Via Benzinga
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China. 
Via Benzinga
OKYO Pharma Reports First Patient Visit For Phase 2 Trial Of OK-101, To Fulfill One Of The Two Phase 3 Studies Required For FDA Approval If Successful
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) announced that the first patient has been screened for its phase 2, multicenter, randomized, double-blinded, placebo-controlled trial, evaluating the... 
Via Benzinga
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
From OKYO Pharma LTD
Via GlobeNewswire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Activates First Clinical Trial Site For Phase 2 Study Of OK-101 To Treat Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) announced the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial,... 
Via Benzinga
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Via ACCESSWIRE
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). 
Via Benzinga
Notice of General Meeting and Publication of Circular
From OKYO Pharma LTD
Via GlobeNewswire
Notice of Intention to Delist From The London Stock Exchange
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4 
Via News Direct
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
By David Willey, Benzinga 
Via TheNewswire.com
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,... 
Via Benzinga
OKYO Pharma Announces PDMR Dealing
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma's Trial Treating Subjects With DED Gets Listed On ClinicalTrials.gov
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public... 
Via Benzinga
Why Is Okyo Pharma (OKYO) Stock Up 13% Today?
Okyo Pharma (OKYO) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of DED treatment OK-101. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
From OKYO Pharma LTD
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.